RVMD stock stays flat after FDA nod for $39,800/month pill
RVMD shares were reported flat despite an FDA nod for a pancreatic cancer pill priced at $39,800 per month.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.